Neurotherapeutics

Gwenn S. Smith; Xiaohua Li; P. Jeffrey Conn

doi:10.1038/npp.2011.233

Neurotherapeutics

Gwenn S. Smith, Xiaohua Li, P. Jeffrey Conn

School of Medicine

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	1-3
Number of pages	3
Journal	Neuropsychopharmacology
Volume	37
Issue number	1
DOIs	https://doi.org/10.1038/npp.2011.233
State	Published - Jan 2012

ASJC Scopus subject areas

Pharmacology
Psychiatry and Mental health

Access to Document

10.1038/npp.2011.233

Cite this

@article{d301ae57a74f4cb7804711e17dc4fa2a,

title = "Neurotherapeutics",

author = "Smith, {Gwenn S.} and Xiaohua Li and Conn, {P. Jeffrey}",

note = "Funding Information: GSS discloses her consultancy for Pfizer, as well as recent research grants from Pfizer and the National Institute of Health (NIMH, NIA). PJC discloses consultancies for Millipore, Seaside Therapeutics, and Karuna Pharmaceuticals, as well as research support from Johnson and Johnson and Seaside Therapeutics. XL discloses grant support from the American Foundation for Suicide Prevention (AFSP), Corcept, Ortho-McNeil-Janssen, Otsuka, and Novartis and the National Institute of Health (NIMH).",

year = "2012",

month = jan,

doi = "10.1038/npp.2011.233",

language = "English (US)",

volume = "37",

pages = "1--3",

journal = "Neuropsychopharmacology",

issn = "0893-133X",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Neurotherapeutics

AU - Smith, Gwenn S.

AU - Li, Xiaohua

AU - Conn, P. Jeffrey

N1 - Funding Information: GSS discloses her consultancy for Pfizer, as well as recent research grants from Pfizer and the National Institute of Health (NIMH, NIA). PJC discloses consultancies for Millipore, Seaside Therapeutics, and Karuna Pharmaceuticals, as well as research support from Johnson and Johnson and Seaside Therapeutics. XL discloses grant support from the American Foundation for Suicide Prevention (AFSP), Corcept, Ortho-McNeil-Janssen, Otsuka, and Novartis and the National Institute of Health (NIMH).

PY - 2012/1

Y1 - 2012/1

UR - http://www.scopus.com/inward/record.url?scp=84862913701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862913701&partnerID=8YFLogxK

U2 - 10.1038/npp.2011.233

DO - 10.1038/npp.2011.233

M3 - Review article

C2 - 22157854

AN - SCOPUS:84862913701

SN - 0893-133X

VL - 37

SP - 1

EP - 3

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

IS - 1

ER -

Neurotherapeutics

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this